Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Marmara Pharmaceutical Journal
2016 , Vol 20 , Issue 2
Gebelikte non-steroidal antiinflamatuvar ilaçların kullanımının değerlendirilmesi
1Hacettepe Üniversitesi, Eczacılık Fakültesi, F.Toksikoloji Anabilim Dalı, Sıhhiye Yerleşkesi Ankara 06100 Türkiye
DOI :
10.12991/mpj.20162059818
Pregnancy is a physiological period that meets the requirements
of developing and growing fetus in uterus. Almost every pregnant
woman is exposed to medicines during pregnancy. The most
sensitive period during pregnancy for the chemical exposure
is organogenesis when the cell division and differentiation rate
are extremely high. Non-steroidal anti-inflammatory drugs
(NSAIDs) are commonly prescribed during pregnancy to treat
fever, pain and inflammation. NSAIDs may have significant
teratogenic effects on fetus. Increased risks of miscarriage
and malformations are associated with NSAID use in early
pregnancy. Exposure to NSAIDs after 30 weeks" of gestation is associated with an increased risk of premature closure of the
fetal ductus arteriosus and oligohydramnios. Fetal and neonatal
adverse effects affecting the brain, kidney, lung, skeleton,
gastrointestinal tract and cardiovascular system have also been
reported with prenatal exposure to NSAIDs. NSAIDs should
be taken during pregnancy only if it is essential at the lowest
effective dose and for the shortest duration possible. This review
focus on the detail about placental transfer and metabolism of
NSAIDs, and the adverse impact of prenatal NSAID exposure.
Keywords :
Nonsteroidal antiinflammatory drugs (NSAIDs), Pregnancy, Teratogen, Organogenesis